A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 271 participants.

Also called NCT02969655

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 271 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02969655
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02969655. Randomized; quadruple masking; primary purpose treatment. Start 2016-11-21 (actual); primary completion 2018-07-02 (actual). Results posted on 2019-11-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)
Condition
Anaemia
Intervention (Drug)
Daprodustat small
Intervention (Drug)
Daprodustat small placebo
Intervention (Drug)
Daprodustat large
Intervention (Drug)
Daprodustat large placebo
Intervention (Drug)
Darbepoetin alfa
Intervention (Drug)
Darbepoetin alfa placebo
Lead sponsor
GlaxoSmithKline (class: industry)

Record details

Record id
cardio:ct-nct02969655
Content hash
882834b6d9eefd262c9be3e6a7ed796fd0f8f9234fce5a76c0c1a6694bcc19e9